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Cystic fibrosis (CF) is a severe disorder, whose main characteristics are, in addition to congenital absence of the vas 
deferens (CAVD), progressive lung disease, pancreatic insufficiency and elevated sweat chloride levels; CAVD 
without any other manifest clinical evidence is commonly suggested to be a form of CF with primarily genital 
expression. We undertook this study to test the hypothesis that men with a CAVD phenotype could be more CF- 
like than it is usually assumed. 
Each subject from a population of 42 patients suffering from CAVD was screened for a panel of 16 mutations 
plus the intron 8 S-thymidine allele of the CF gene (5T), and underwent a thorough clinical evaluation which 
included a detailed anamnesis, anthropometric data, chest and paranasal sinuses X-rays, pulmonary function tests, 
sputum cultures, stool chymotrypsin determination, sweat test and, in a limited number of patients, Nasal Potential 
Difference (NPD) measurement. 
The genotype analysis detected one compound heterozygote, 23 heterozygotes and 15 individuals carrying the 5T 
allele; sweat chloride was positive in six, borderline in 11 and negative in 25 subjects; NPD was abnormal in 2/12 
patients. Medical history and clinical examination were consistent with respiratory disease in 20 cases; there was 
radiological evidence of pulmonary hyperinflation in 37139 and of sinus disease in 20142 patients; Staphylococcus 
aureus was cultivated in the sputum of 9136, Haemophilus injluentiae in 3136 subjects and three patients showed 
functional evidence of airway obstruction. These findings were equally distributed among sweat positive, borderline 
and negative patients. 
These results raise questions about the supposed benignancy of the CAVD condition. A close follow-up of men 
with CAVD could ascertain potential complications. 
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Introduction 
Up to 6% of infertile men are affected by Congenital 
Bilateral Absence of the Vas Deferens (CBAVD), a disorder 
characterized by antenatal regression of the deferent ductal 
system of the male genital tract (1). A genetic basis for 
CBAVD has been provided by its association with Cystic 
Fibrosis (CF), the most common severe autosomal recessive 
disorder in Caucasian populations, which in its classical 
form is characterized by chronic pulmonary infections, 
exocrine pancreatic insufficiency, elevated sweat electrolytes 
and CBAVD. In 1989 the CF gene was identified and 
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designated as the CF Transmembrane Conductance Reg- 
ulator (CFTR) gene; since its discovery more than 600 
mutations have been identified (24). 
CBAVD patients have been reported (5-8) as carrying 
CFTR mutations much more frequently than the general 
population. Also, in 1995 Chillon et al. (9) demonstrated 
that the 5T variant of a polypyrimidine tract in intron 8 of 
the CFTR gene (5T), which may cause reduced levels of the 
normal CFTR protein (lo), is represented to a greater 
extent in CBAVD patients than in the general population. 
In a few of those with CBAVD CF mutations or 
polymorphic variants can be detected on each of the two 
copies of the gene, but many others have only one identified 
CFTR defect; however, it is now widely assumed that most 
men with CBAVD found to be carrier for a CFTR 
mutation are actually compound heterozygotes, even 
though the mutation on the other chromosome has not 
yet been identified, possibly being in the promoteraegion or 
in non-coding regions of CFTR. 
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A condition very similar to CBAVD is Congenital 
Unilateral Absence of the Vas Deferens, which also can 
be related to dysfunctional CFTR; a high frequency of 
detectable CF gene mutations and positive or border- 
line sweat tests has also been reported in these subjects 
(7311). 
As far as clinical manifestations are concerned, CF and 
both Bilateral and Unilateral Congenital Absence of the 
Vas Deferens (CAVD) have therefore been postulated to be 
the phenotypic extremes of a spectrum resulting from 
various combinations of mutations in the CFTR gene (12). 
However, so far it is not yet clear where in this spectrum 
CAVD ends and CF begins, and to what extent men with 
CAVD could actually have other features consistent with a 
CF diagnosis. 
In this study we performed an analysis of 16 CFTR 
mutations as well as of the CFTR intron poly(T) tract 
length in a population of 42 men with CAVD. A thorough 
examination of their clinical features, aimed at deter- 
mining possible clinical evidence of mild CF, is also 
reported. 
Materials and methods 
SUBJECTS 
The population evaluated consisted of 42 men (mean age 
33 years, range 19-53 years), consecutively included in the 
study between June 1995 and November 1997. All of them 
originally requested consultation in departments specialized 
in diagnosing and treating infertility, where the diagnosis of 
CAVD was established on the basis of azoospermia with 
normal-sized testes, non-palpable vas deferens and small 
volume and low pH of the ejaculate. Thirty-nine of them 
had CBAVD and three (no. 8, 24 and 33) had monolateral 
absence of the vas deferens. They were referred to our 
Center for CFTR testing and genetic counselling of patients 
and their partners before undergoing assisted reproductive 
techniques. Informed consent was obtained from all 
patients. 
CLINICAL EVALUATION 
All subjects had a detailed anamnesis taken that included 
familial history of CF or male infertility, as well as 
questions about respiratory, gastrointestinal, pancreatic 
and hepatobiliary disease (Table l), and were meticulously 
examined by a registrar skilled in CF clinic. 
The respiratory parameters evaluated were: 
1. Posteroanterior and lateral chest X-rays. The degree of 
pulmonary involvement was assessed using the 
Chrispin-Norman score (13). This score categorizes 
over-expansion on the lateral film, and bronchial line 
shadows, nodular shadows, ring shadows and large 
shadows in each of four quadrants on the 
posteroanterior film, and ranges from 0 (normality) to 
38 (massive pulmonary destruction, detectable in final 
TABLE 1. Anamnesis specific for CF-compatible signs and 
symptoms 
Familial 
Respiratory 
Gastrointestinal 
Hepatobiliary 
Other 
Relations with CF 
Deaths in childhood 
Infertility in siblings 
Sinusitis 
Nasal polyps 
Asthma 
Chronic cough 
Prolonged bronchorrea 
Recurrent pneumonia 
Pneumothorax 
Haemoptysis 
Allergic bronchopulmonary 
aspergillosis 
Radiographic evidence of bronchiec- 
tasis or atelectasis 
Meconium ileus 
Distal intestinal obstructive 
syndrome ( = need for enemas, 
intestinal lavage or surgery 
after the neonatal period) 
Failure to thrive 
Abdominal pain 
Stool consistency and frequency 
Abdominal surgery 
Rectal prolapse 
Pancreatitis 
Neonatal jaundice 
Evidence for liver disfunction 
Gallbladder disease 
Abdominal pain 
Diabetes mellitus 
Delayed puberty 
stages of CF). It was calculated and blindly assigned by 
a single examiner (GM). 
2. Paranasal sinuses X-rays. 
3. Respiratory function, evaluated by forced vital capacity 
(FVC), forced expiratory volume in 1 set (FEVt) and 
forced expiratory flow in the middle half of expiration 
FEF257s) by bell spirometry (Biomedin, Padua, Italy). 
A reduction with respect to the predicted value < 80% 
for FEVt or ~88% for FEVr/FVC was considered 
indicative of airway obstruction ( 14,15). 
4. Bacteriological cultures of deep sputum samples 
or hypopharingeal secretions obtained after 
physiotherapy and coughing (one culture per patient). 
Gastrointestinal and nutritional status were assessed by: 
1. Weight and height Z-scores for chronological age 
according to the WHO reference values (16). 
2. Serum glutamil-oxaloacetic transaminase, glutamil- 
pyruvic transaminase, gamma-glutamil transpeptidase, 
bilirubin, pancreatic amilase and lipase. 
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3. Serum immunoreactive trypsin (IRT) (Pharmacia 
standardised Delfia IRT kit, Uppsala, Sweden) (17). 
4. Stool chymotrypsin levels (Boerhinger Mannheim kit, 
Mannheim, Germany). 
Sweat electrolyte analysis was performed twice by the 
classic Gibson and Cooke method (18). At least 100 mg of 
sweat for a stimulation/collection skin area of 3.2 x 3.2 cm 
had to be collected on a 4 x 4 cm filter paper in order to 
consider the sweat test reliable. The mean value for both 
electrolytes obtained in the two sweat tests is reported in 
this article. Chloride levels above 60 mEq kg-’ were 
considered positive, between 40 and 60 mEq kg-’ border- 
line and below 40 mEq kg-’ negative. 
Basal nasal potential difference (NPD) was measured in 
12 patients with no acute upper airway infection or 
previous nasal surgery, according to the method described 
by Alton et al. (19). 
While the study was already in progress, we added 
abdominal ultrasonography to the above mentioned 
routine, in order to detect associated congenital renal 
abnormalities; 16 patients were thereafter tested. 
MUTATION ANALYSIS 
The mutations analysed were AF508, AI507, R117H, 
R1162X, 2183AA-+G, N1303K, 3849+10KbC+T, 
G542X, 1717-lG+A, R553X, Q552X, G85E, 
711+ 5G+A, W1282X, 3132delTG and 2789 + 5G+A, 
plus the CFTR intron 8 poly(T) tract length. The 16 
mutations are expected to cover approximately 72% of CF 
chromosomes in the Italian population (20,21). 
All the mutations were analysed by a Reverse Dot Blot 
Assay based on those described by Chehab et al. (22), with 
the exception of R117H, for which we used a restriction site 
generating PCR (23), and designed two primers: RI 17H-D 
[ACC CGG ATA ACA AGG AGG AGC] and R117H-R 
[GGC CTG TGC AAG GAA GTA TTJ which create a CfoI 
restriction site when the mutation is absent. With this primer 
pair the region spanning the mutation was amplified from 
genomic DNA of CBAVD patients. The PCR products were 
digested with CfoI and visualized on a 3% agar gel. 
The intron 8 polyT sequence was analysed with the 
nested-PCR method according to Chillon et al. (9). 
Results 
Tables 24 show genetic, clinical and respiratory data of 
the 42 patients, catalogued by decreasing order of sweat 
chloride levels. Table 2 deals with the six patients who had a 
sweat chloride higher than 60 mEq kg-‘, while Tables 3 
and 4 list respectively the 11 patients with borderline and 
the 25 with negative sweat test. 
Among the 84 studied chromosomes we identified 24 
CFTR mutations; one patient (2.4%) was a compound 
heterozygote, 22 patients (52.3%) had mutations in only 
one CFTR allele. The overall frequency of CF mutations 
detected was 28.6% (24/84), significantly higher than the 
one expected in the general population (P=O.OOl). As for 
the 5T allele, it was identified in 16 of the 84 (19%) 
chromosomes assayed, a frequency four times higher than 
the 5% in the Italian population (24). In concordance with 
its role in the pathogenesis of CAVD, the 5T variant was 
not found in the only patient with mutations on both copies 
of the CFTR gene, but in 41% (9/22) of those with a single 
gene mutation and in 26% (5/19) of patients with CAVD 
and no previously identified CFTR mutations. 
Nasal epithelial bioelectric properties in the 12 patients in 
whom basal NPD was measured were normal as a whole 
(- 13.7+ 10.48 mV). However two patients showed values 
lower than -28 mV (-46.7 mV in patient no. 4 and 
-29.1mV in no. 25) which is considered to be the normal 
limit for basal NPD at our Center, on the basis of 
previously reported data (25). 
Medical history disclosed a positive familial CF case in 
one patient (no.1) and two infant deaths compatible with 
CF in another (no. 25); close male relatives of three subjects 
(nos. 3, 7 and 9) were reported to be infertile. Associated 
nephrourological peculiarities were: monolateral varicocele 
in patient nos. 7, 23 and 24; renal agenesis in patients 29 
and 32; renal cysts in patients 22 and 35; and criptorchism, 
inguinal hernia and monarchism respectively in patient nos. 
10, 18 and 29. 
TABLE 2. Sweat chloride concentration, genotype and respiratory data of the subjects under study with positive sweat test 
Patient Sweat Cl- CFTR PolyT Respiratory Chrispin- Mucosal Sputum FEV,/FVC 
(mEq kg-‘) mutations splice medical history and Norman thickening of microbiology (%I 
variant physical examination score paranasal sinuses 
1 88 AF508 919 TB lymphadenitis 1 fr/max neg 94 
2 78.5 AF508 519 2 no neg 103 
3 68 - 517 pneumothorax5nasal polyps5 5 fr/max neg 97 
4 65 AF508 719 nasal polyps” 4 no St aur 117 
5 63.5 AF508 519 sinusitis5 3 no neg 104 
6 62 AF508 719 4 max neg 109 
Mucosal thickening of paranasal sinuses determined by X-rays: fr: frontal sinuses; max: maxillary sinuses. St aur: 
Staphilococcus aureus; neg: negative. 5CF-compatible signs and symptoms 
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TABLE 3. Sweat chloride concentration, genotype and respiratory data of the subjects under study with borderline sweat test 
Patient Sweat Cl- CFTR PolyT Respiratory Chrispin- Mucosal sputum FEVJFVC 
(mEq kg-‘) mutations splice medical history and Norman thickening of microbiology W) 
variant physical examination score paranasal 
sinuses 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
60 R117H 717 
58 515 
56 AF508 519 
54.5 AF508 719 
53 AF508 519 
51.5 R553X 517 
44.5 AF508 919 
44.5 - 717 
43.5 1717-1G +A 517 
41.75 R1162X 517 
40.5 AF508 519 
4 no 
sinusitis5 7 no 
6 max 
sinusitis§ 2 fr 
1 fr 
allergic rhinitis, asthama 3 max 
thoracic kyphosis” 6 fr/max 
1 no 
sinusiti$ 2 fr 
5 no 
sinusitis5 nasal polyps” 1 fr/max 
n-23 109 
neg 93 
St aur 109 
St aur 111 
St aur 97 
* 106 
Haem in 100 
neg 95 
w 104 
neg 99 
* 112 
Mucosal thickening of paranasal sinuses by X-rays: fr: frontal sinuses; max = maxillary sinuses. St aur: Stuphilococcus aureus; 
Haem in: Haemophilus influentiae. *no available data;5CF-compatible signs and symptoms. 
TABLE 4. Sweat chloride concentration, genotype and respiratory data of the subjects under study with negative sweat test 
Patient Sweat Cl- CFTR PolyT Respiratory Chrispin- Mucosal Sputum FEVJFVC 
(mEq kt- ‘) mutations splice medical history and Norman score thickening of microbiology W) 
variant physical examination paranasal sinues 
18 39 - 717 
19 35.5 G542X 719 
20 34.5 AF508 719 
21 34 2183AA+G 717 
22 33.5 R553X 517 
23 33.5 - 519 
24 33.5 - 517 
25 32 AF508lR117H 7/9 
26 30.5 R1162X 517 
21 30.5 - 717 
28 29.5 G542X 719 
29 23.5 719 
30 21.5 717 
31 21 - 717 
32 20.5 - 717 
33 20 717 
34 19.5 717 
35 18 R1162X 717 
36 18 717 
37 17.5 719 
38 17 AF508 719 
39 16 - 717 
40 12.5 717 
41 8.5 719 
42 6 517 
TB primary infection 
chronic cough5 
funnel chest@ 
sinusitis5 
nasal polyps5 
funnel chest5 
thoracic kyphosi$ 
nasal polyps” 
sinusitis8 
hearing loss 
chronic coughs 
* no 
5 no 
4 max 
2 no 
2 fr/max/ethm 
7 no 
3 no 
11 no 
2 fr 
7 max 
* fr 
3 no 
8 no 
4 max 
1 no 
* fr/max 
3 no 
6 no 
3 fr 
13 no 
fr/max 
no 
fr/max 
no 
no 
St aur 101 
St aur 101 
* 107 
Haem in 89 
neg 99 
neg 109 
neg 97 
neg 109 
* 108 
neg 104 
* 97 
neg 105 
St aur 102 
neg 107 
* 109 
w 103 
Haem in 100 
St aur 97 
St aur 108 
neg 66 
neg 105 
neg 96 
neg 84 
wit 99 
neg 82 
Mucosal thickening of paranasal sinuses by X-rays: fr: frontal sinuses; max = maxillary sinuses. St aur: Staphilococcus aureus; 
Haem in: Huemophilus influentiae. *no available data; 5CF-compatible signs and symptoms. 
MILD RESPIRATORY DISEASE AND ABSENCE OF VAS DEFERENS 873 
The gathering of respiratory data emphasized a history 
or a clinical examination consistent with respiratory disease 
in 20 (48%) cases. In particular, 16 of them (38%) had one 
or more signs and symptoms frequently found in CF, i.e. 
sinusitis, nasal polyps, thoracic kyphosis, funnel chest, 
chronic cough and pneumothorax. Six patients had never 
smoked (nos. 1, 5, 20,24, 30 and 34), one had quit smoking 
more than 2 yr prior to the study (no. lo), three smoked 
between one and 10 cigarettes per day (nos. 7, 13, and 41) 
and five smoked more than 20 cigarettes per day (nos. 18, 
35, 36, 39 and 40); smoking history for the remaining 27 
patients is unknown. Paranasal sinuses X-rays and sputum 
microbiology results are detailed in Tables 24. The 
Chrispin-Norman score in the 39 patients in whom chest 
X-rays were performed ranged from 1-13 (mean 4.28 
SD + 2.68); signs of pulmonary hyperinflation (depression of 
the diaphragm with loss of its normal curvature and/or 
increase in the retrosternal airspace and/or thoracic 
kyphosis) were detected in the chest radiographs of 37 of 
these 39 patients. The mean pulmonary function values 
were on the whole normal (95.73 + Sol 1.13 for FVC, 
99.97fs~13.20 for FEVi and 103.23fso31.5 for 
FEFz5-,& but a low FEVJFVC ratio was found in 
patients nos. 37, 40 and 42. In particular, patient no. 40 
added to a severe bronchial obstruction major chest X-rays 
involvement and an evident kyphosis. 
The gastroenterological and nutritional assessment de- 
tected hepatomegalia in one subject. No clear signs of 
malnutrition could be observed (mean weight and height Z- 
scores were respectively 0.41 fs~0.87 and -0.125 *SD 
0.88) but patient no. 5 had a height Z-score of -2.09. 
Pancreatic function tests were altogether normal, the 
average values being of 15.76+so11.7 units wet stool 
gram- ’ for fecal chymotrypsin, 16.26fs09.86 ug 1-l for 
IRT and respectively 64.29 f ~~27.25 and 72.39 f ~~44.68 
Ull’ for serum pancreatic amilase and serum lipase. 
However, in patients no. 30 and 38 fecal chymotrypsin 
were low and in patient no. 4 serum amilase and lipase were 
above normal reference values. Liver function tests were 
always within normal ranges. 
Discussion 
The classical CF manifestations are chronic obstructive 
lung disease with recurrent infections, pancreatic insuffi- 
ciency and, in males, bilateral absence of the vas deferens; 
other, less common, clinical findings include meconium 
ileus, nasal polyposis and hepatobiliary disease. In addi- 
tion, unusual forms of CF have been identified, which are 
often characterized by survival into adulthood, mild 
chronic sinopulmonary disease, pancreatic sufficiency and 
normal to borderline sweat electrolyte values. 
Among these atypical forms CAVD holds a peculiar 
position: men with CAVD are usually reported to have no 
major evidence of respiratory tract or pancreatic abnor- 
malities; their condition is therefore considered worth being 
monitored, but on the whole capable of negligible clinical 
impact (6,26). A recent consensus statement from the Cystic 
Fibrosis Foundation (27) recommends a close follow-up for 
the development of CF-related complications only in those 
individuals presenting with obstructive azoospermia in 
whom a diagnosis of CF could be formulated. The 
criterium for such diagnosis is considered to be the evidence 
of CFTR dysfunction as documented by elevated sweat 
chloride concentrations, or identification of two CF 
mutations, or the in vivo demonstration of abnormal ion 
transport across the nasal epithelium. 
According to these criteria, only seven of our patients 
could be labelled as affected by CF, six because of positive 
sweat tests and one because of abnormal nasal epithelial 
bioelectric properties, the latter being also a compound 
heterozygote. However, in consideration of the actual limits 
of these diagnostic aids (28,29), we thought it helpful to 
carry out in our patients a comprehensive clinical, radio- 
graphical and laboratory evaluation for features known to 
be consistent with the CF phenotype. 
On the whole only three patients (nos. 14, 29 and 32) 
were free of any anamnestical, clinical, biochemical, 
radiological, microbiological or spirometric features com- 
patible with CF, and among them two had renal agenesis 
(nos. 29 and 32). This was not a unexpected result, as a 
prominent exception to the genetic commonality of CF and 
CAVD is represented by men with both CAVD and renal 
abnormalities, in whom it has been postulated that the vas 
deferens absence has a genetic and embryological basis not 
related to any CFTR dysfunctions (12,30). Our data further 
supported this hypothesis, as no CFTR mutations were 
detected in the two patients in which CAVD was associated 
with renal agenesis. 
The results of the clinical evaluation of our patients 
are partially in concordance with those of Durieu et al. 
(31) who documented in a series of 14 men with CAVD 
a high frequency of radiological evidence of sinus 
disease and of elevated antibodies to Pseudomonas 
aeruginosa, and of D&k (32), who found in 26 CAVD 
males clinical symptoms that most frequently involved 
the upper respiratory tract. Conversely, Anguiano et al. 
(6) affirmed that none in a group of 25 patients with 
CBAVD had any manifestations of pulmonary or gastro- 
intestinal disease and Colin et al. (26) found no clinical 
evidence for CF in 18 patients with CBAVD in whom they 
evaluated clinical status, growth, nutritional state and 
respiratory function; in the latter study though, chest and 
paranasal sinuses X-rays and sputum cultures were not 
included. 
We found a good correlation between elevated sweat 
chloride and. CFTR analysis; 14 of the 17 patients with 
positive or borderline sweat test carried one of the sought 
mutations. Among the remaining three, one carried two 5T 
alleles and another had a polyT genotype 5T/7T. 
On the other hand, only approximately half (12/25) of 
the individuals with low sweat chloride carried either a 
CFTR mutation or a 5T variant or both. However, the 
frequency of features compatible with CF in the negative 
sweat test patients was similar to that in patients with raised 
or borderline sweat chloride. Besides, the group with 
normal sweat electrolytes also includes some interesting 
cases, like the only compound heterozygous patient we 
managed to detect (no. 25), and one patient (no. 37) with 
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remarkable physical, radiological and functional signs of 
lung disease. 
Our conclusions are that, even though a proper diagnosis 
of CF can be made in only a minority of subjects, patients 
with CAVD show minor but not negligible signs of 
respiratory disease in almost every case. A negative sweat 
test should not be considered sufficient to exclude the 
possibility of developing future signs of CF. As the long- 
term prognosis of men with CAVD is unknown, it could be 
worth planning pilot studies aimed at monitoring all these 
subjects (with the possible exception of the ones with renal 
agenesis) for clinical features compatible with CF. Until 
further data become available, it seems anyway sensible to 
proceed with caution, and avoid labelling CAVD as a 
clinical equivalent of CF. 
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